Lupin taps Abdelaziz Toumi as CEO of API CDMO subsidiary

Lupin is welcoming a new executive. Abdelaziz Toumi (Abdel) is joining as CEO of the company’s newly formed subsidiary, Lupin Manufacturing Solutions. LMS is engaged in the development, manufacture and sale of Active Pharmaceutical Ingredients and is starting to build its Contract Development and Manufacturing Operations business.

Toumi is a seasoned leader with a blend of scientific and commercial skills, and brings more than two decades of experience in the biotech, pharma and CDMO sectors, spanning Europe, North America and Asia. He has held leadership positions at Bayer, Merck, Catalent, Lonza and KBI Biopharma, where he was responsible for driving growth, innovation and operational excellence. 

He will be based in Switzerland and will spend considerable time in India.

Lupin receives FDA nod for generic Lotemax

Toumi holds a Doctorate in Chemical Engineering and a Master’s degree in Business Administration from the University of Southern Queensland.

Lupin’s managing director, Nilesh Gupta said, “We are delighted to welcome Abdel to our team. He brings a wealth of knowledge and experience in the API CDMO space and will be instrumental in establishing LMS as a trusted and preferred partner for our global customers.”

[Read more: Lupin receives FDA nod for 3 generics]